Search

Displaying results 2401 - 2410 of 6198 in total
  1. Drug

    Cyproheptadine

    go.drugbank.com/drugs/DB00434
    ApprovedInvestigational

    Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in ...

  2. Drug

    Meprobamate

    go.drugbank.com/drugs/DB00371
    ApprovedIllicit

    It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. … Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated).

  3. Target

    Acyl carrier protein

    go.drugbank.com/bio_entities/BE0001948
    TargetSalmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)

    Carrier of the growing fatty acid chain in fatty acid biosynthesis.

    Synonyms: CAF
  4. Target

    Acyl carrier protein

    go.drugbank.com/bio_entities/BE0004133
    TargetEscherichia coli (strain K12)

    Carrier of the growing fatty acid chain in fatty acid biosynthesis.

    Synonyms: CAF
  5. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and ha...

  6. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.

  7. Drug

    4'-Methylene-5,8,10-trideazaaminopterin

    go.drugbank.com/drugs/DB05616
    Investigational

    CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier

  8. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  9. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. Eculizumab was granted FD...

  10. Drug

    Apraclonidine

    go.drugbank.com/drugs/DB00964
    ApprovedInvestigational

    It is an alpha2-adrenergic agonist.